Home › NDC Lookup › RxCUI directory › RxCUI 2265735

24 HR asenapine 0.317 MG/HR Transdermal System [Secuado] — RxCUI 2265735

RxNorm drug concept · Semantic branded drug
RxCUI 2265735 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2265735
Official name24 HR asenapine 0.317 MG/HR Transdermal System [Secuado]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asSecuado 7.6 MG/Day 24 HR Transdermal System; SECUADO 7.6 MG/Day 24HR Transdermal System; 24 HR Secuado 0.317 MG/HR Transdermal System
FDA products mapped3
Package NDCs mapped6
Reported Medicaid activity (SDUD)1,433 prescriptions · 13 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Asenapine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • This is really important — swallowing the tablet dramatically reduces how much of the medication actually gets into your system. When it dissolves under your tongue, it absorbs dir...
  • Why do I have to let the tablet dissolve under my tongue instead of just swallowing it?
  • Yes, sleepiness and dizziness are among the most commonly reported side effects, especially early on. The dizziness can be worse when you stand up quickly, because asenapine can ca...
  • I feel really sleepy and dizzy since starting this — is that normal?
📖 Read our full Asenapine guide →

🕸️ Concept Web — How 24 HR asenapine 0.317 MG/HR Transdermal System [... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR asenapine 0.317 MG/HR Transdermal System [Secuado] RxCUI 2265735

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Asenapine 784649
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Secuado 2265724
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Asenapine Transdermal System 2261740
    • Asenapine Topical Product 2261738
    • Asenapine Transdermal Product 2261739
    • Asenapine Transdermal System [Secuado] 2265726
    • Secuado Topical Product 2265727
    • Secuado Transdermal Product 2265728
    • Transdermal System 316987
    • Topical Product 1151122
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 24 HR asenapine 0.317 MG/HR Transdermal System SCD · 2261758
  • Asenapine 0.317 MG/HR SCDC · 2261757
  • Asenapine Transdermal System SCDF · 2261740
  • Asenapine Topical Product SCDG · 2261738
  • Asenapine Transdermal Product SCDG · 2261739

Brand-Name Concepts

  • Asenapine 0.317 MG/HR [Secuado] SBDC · 2265734
  • Asenapine Transdermal System [Secuado] SBDF · 2265726
  • Secuado Topical Product SBDG · 2265727
  • Secuado Transdermal Product SBDG · 2265728
  • Secuado BN · 2265724

📦 FDA Products & Package NDCs

3 products · 6 package NDCs
6 package NDCs map to RxCUI 2265735 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
68968-0172-03 30 POUCH in 1 CARTON (68968-0172-3) / 1 d in 1 POUCH SECUADO Noven Therapeutics, LLC 2020-02-12
68968-0172-07 7 POUCH in 1 CARTON (68968-0172-7) / 1 d in 1 POUCH SECUADO Noven Therapeutics, LLC 2020-02-12
68968-0173-03 30 POUCH in 1 CARTON (68968-0173-3) / 1 d in 1 POUCH SECUADO Noven Therapeutics, LLC 2020-02-12
68968-0173-07 7 POUCH in 1 CARTON (68968-0173-7) / 1 d in 1 POUCH SECUADO Noven Therapeutics, LLC 2020-02-12
68968-0174-03 30 POUCH in 1 CARTON (68968-0174-3) / 1 d in 1 POUCH SECUADO Noven Therapeutics, LLC 2020-02-12
68968-0174-07 7 POUCH in 1 CARTON (68968-0174-7) / 1 d in 1 POUCH SECUADO Noven Therapeutics, LLC 2020-02-12
Observed labelers: Noven Therapeutics, LLC (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.